Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3415)	4/12/2001 8:08:20 PM
From: Biomaven	Respond to of 52153

VRTX: 2000 1999 1998 ------------------- ------------------- ------------------- WEIGHTED WEIGHTED WEIGHTED AVERAGE AVERAGE AVERAGE EXERCISE EXERCISE EXERCISE SHARES PRICE SHARES PRICE SHARES PRICE -------- -------- -------- -------- -------- -------- <S> <C> <C> <C> <C> <C> <C> Outstanding at beginning of year................. 13,488 $11.75 11,674 $11.31 9,404 $11.01 Granted.......................................... 2,741 66.50 2,630 13.00 2,682 12.29 Exercised........................................ (3,788) 10.57 (488) 7.62 (156) 7.45 Canceled......................................... (246) 15.18 (328) 13.59 (256) 12.95 ------ ------ ------ ------ ------ ------ Outstanding at end of year....................... 12,195 24.35 13,488 11.75 11,674 11.31 ====== ====== ====== Options exercisable at year-end.................. 5,194 $11.84 6,880 $10.29 5,516 $ 9.38

To: Biomaven who wrote (3415)	4/12/2001 8:16:06 PM
From: Miljenko Zuanic	Respond to of 52153

Peter and others, Seams that STREET did FOUND near term catalyst for bio-sector. Very good earning so far (from pharma and bios, more rosy from bios) with good perspective will ignite interest again. That there is sector which can generate revenue growth regardless of the current economy. Also upcoming neurology/psychiatry, oncology, gastroenterology, endocrinology, …you-name-it-logy ,…meetings will point to good progress in bioscience. Cramer &Co. can eat his shoes if he didn't already (or if John M. let him, it may be restriction in many psychiatric trials enrollment protocol, drug-drug interaction?). Miljenko PS: Interesting options numbers for VRTX.